Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TACR3 | P29371 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4556318 | 0.90 | KDM4E (0.55) | KDM4ESMN1; SMN2ALDH1A1TACR3MEN1 | |
| SCHEMBL13223030 | 0.90 | KDM4E (0.49) | KDM4ESMN1; SMN2ALDH1A1TACR3MEN1 | |
| SCHEMBL3045119 | 0.90 | KDM4E (0.54) | KDM4ESMN1; SMN2ALDH1A1TACR3MEN1 | |
| SCHEMBL3155976 | 0.90 | KDM4E (0.54) | KDM4ESMN1; SMN2ALDH1A1TACR3MEN1 | |
| SCHEMBL13223031 | 0.89 | TACR3 (0.56) | KDM4ESMN1; SMN2ALDH1A1TACR3MEN1 | |
| SCHEMBL19192873 | 0.87 | TDP1 (0.50) | KDM4ESMN1; SMN2ALDH1A1TACR3MEN1 | |
| SCHEMBL8505490 | 0.86 | KDM4E (0.51) | KDM4ESMN1; SMN2ALDH1A1TACR3MEN1 | |
| SCHEMBL8261052 | 0.86 | KDM4E (0.50) | KDM4ESMN1; SMN2ALDH1A1TACR3MEN1 | |
| SCHEMBL375146 | 0.86 | KDM4E (0.50) | KDM4ESMN1; SMN2ALDH1A1TACR3MEN1 | |
| SCHEMBL2617528 | 0.86 | KDM4E (0.50) | KDM4ESMN1; SMN2ALDH1A1TACR3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| EP-2066688-A2 | MACROCYCLIC HCV INHIBITORS AND THEIR USES | Novartis AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008033389-A2 | MACROCYCLIC HCV INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | KDM4E 4021/4885SMN1; SMN2 877/4885ALDH1A1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.